Abbott Laboratories Stock Drops to $88.18 Amid Broad Healthcare Selloff
3h ago|3 min readQuick Read
Fazen Markets Editorial Desk
Collective editorial team · methodology
abbott-laboratoriesABT
Fazen Markets Editorial Desk
Collective editorial team · methodology
Trades XAUUSD 24/5 on autopilot. Verified Myfxbook performance. Free forever.
Risk warning: CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. The majority of retail investor accounts lose money when trading CFDs. Vortex HFT is informational software — not investment advice. Past performance does not guarantee future results.
Abbott Laboratories shares traded at $88.18 in midday trading on 14 June 2026, down 1.11% for the session. The stock has traded between $87.07 and $90.29 as healthcare stocks broadly retreat. Finance.yahoo.com reported on 13 June that the stock is being evaluated for its longevity investment potential, a theme sensitive to Federal Reserve policy and sector rotation.
The current pullback in Abbott stock coincides with a broader re-rating of healthcare and longevity-focused equities. The S&P 500 Health Care sector is down approximately 7% year-to-date, underperforming the broader S&P 500. This trend is partly driven by a higher-for-longer interest rate environment, where elevated yields pressure the valuation of growth-oriented medical names. The last significant sector-wide pressure occurred in late 2023, when the 10-year Treasury yield first breached 4.5%, triggering a 15% correction in the iShares U.S. Medical Devices ETF (IHI) over six weeks. The immediate catalyst now is a rotation into cyclical sectors, as investors anticipate stronger economic data could delay rate cuts. This has left defensive, dividend-paying stocks like Abbott vulnerable despite its stable earnings profile.
Abbott's intraday low of $87.07 on 14 June marks a retreat from a 52-week high of $126.45, representing a peak-to-trough decline of roughly 31%. The stock's current dividend yield, based on the $88.18 price, is approximately 2.2%. This compares to a peer group average of 1.8% for large-cap medical device companies. Abbott's forward price-to-earnings ratio sits near 23x, a premium to the S&P 500's 20x but a discount to its own 5-year average of 26x. The following table highlights key valuation shifts for Abbott over the past year:
| Metric | 14 June 2025 | 14 June 2026 | Change |
|---|---|---|---|
| Stock Price | $112.50 | $88.18 | -21.6% |
| P/E Ratio | 27.5x | 23.0x | -16.4% |
| Dividend Yield | 1.9% | 2.2% | +30 bps |
The stock’s 1.11% daily decline also underperformed the S&P 500, which was down only 0.3% at the same time.
The pressure on Abbott signals a risk-off stance within the medical technology sector. Second-order effects could benefit lower-multiple, high-volume device makers like Medtronic (MDT) or pure-play pharmaceutical firms with stronger near-term pipelines. Companies leveraged to aging demographics but with less exposure to elective procedures, such as diabetes care leader Dexcom (DXCM), may see relative outperformance if procedure volumes slow. A key limitation to the bearish view is Abbott's diversified revenue base, spanning diagnostics, medical devices, and nutrition, which provides stability. Institutional positioning data from the latest 13F filings shows hedge funds have been net sellers of Abbott over the past quarter, while long-only funds have maintained core holdings. Flow analysis indicates capital moving out of broad healthcare ETFs and into select biotechnology names ahead of key clinical trial readouts.
Two immediate catalysts will determine Abbott's trajectory. The company is scheduled to report Q2 2026 earnings on 17 July 2026, with analysts focused on guidance for its Freestyle Libre continuous glucose monitor franchise. The next Federal Open Market Committee meeting on 22 July 2026 will also be critical; any dovish shift could relieve valuation pressure on the entire sector. Technically, the $85 level represents a multi-year support zone dating to 2022; a sustained break below could target $78. On the upside, a close above the 50-day moving average near $92.50 would signal a potential near-term recovery. Investors should monitor the 10-year Treasury yield; a sustained move below 4.0% would likely trigger a sector-wide rally.
At a 2.2% yield based on the current $88.18 price, Abbott's dividend is attractive relative to its peers and the broader market. The company has increased its dividend for over 50 consecutive years, qualifying it as a Dividend King. However, the stock's total return will depend more on earnings growth and multiple expansion than the dividend alone, especially in a higher-rate environment.
Abbott trades at a forward P/E of 23x. This is a premium to more mature peers like Medtronic (20x) but a notable discount to high-growth, pure-play longevity names like Unity Biotechnology (UBX) which, while not directly comparable, often trade on revenue multiples exceeding 10x due to their earlier stage. Abbott offers a blend of growth and income not found in most biotech longevity plays.
The core risk is technological disruption within its key markets, particularly glucose monitoring and structural heart devices. New entrants using non-invasive or implantable sensor technology could erode Abbott's substantial market share in diabetes care. prolonged inflation squeezing hospital budgets could delay capital equipment purchases, impacting its medical device division's growth.
Abbott's current price reflects broad sector headwinds more than a deterioration in its fundamental business durability.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. CFD trading carries high risk of capital loss.
Vortex HFT is our free MT4/MT5 Expert Advisor. Verified Myfxbook performance. No subscription. No fees. Trades 24/5.
Position yourself for the macro moves discussed above
Start TradingSponsored
Open a demo account in 30 seconds. No deposit required.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.